Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother.
Harms
Gundel
G
Kunz
Andrea
A
Karcher
Heiko
H
Mugenyi
Kizito
K
Kurowski
Michael
M
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002584:Cervix Uteri / Q000737:chemistry* / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D019829:Nevirapine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009960:Oropharynx / Q000737:chemistry* / Q000378:metabolism; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014621:Vagina / Q000737:chemistry* / Q000378:metabolism
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine